Myostatin is an important link in the pathogenesis of protein-energy deficiency in patients on program hemodialysis
- Authors: Yakovenko A.A.1, Yesayan A.M.1, Lavrishcheva Y.V.2, Rumyantsev A.S.3
-
Affiliations:
- Pavlov University
- Almazov National Medical Research Center
- St. Petersburg State University
- Issue: Vol 15, No 4 (2023)
- Pages: 5-10
- Section: Original Articles
- URL: https://journals.rcsi.science/2075-3594/article/view/257759
- DOI: https://doi.org/10.18565/nephrology.2023.4.5-10
- ID: 257759
Cite item
Open Access
Access granted
Subscription Access
Abstract
Objective. Evaluation of the relationship between serum myostatin levels and indicators of protein-energy malnutrition (PEM) in patients on program hemodialysis (PHD).
Material and methods. 645 patients on program HD were examined, among them 300 men and 345 women aged 56.8±12.8 years. All patients received treatment with program HD for 8.4±5.3 years. Assessment of nutritional status for the purpose of diagnosing PEM was carried out using the method proposed by ISRNM (International Society of Renal Nutrition and Metabolism). The blood serum myostatin level was determined by a method based on the principle of competitive enzyme immunoassay using mono- and polyclonal antibodies to myostatin using a commercial kit “Myostatin ELISA” (Immunodiagnostik, Germany) in accordance with the manufacturer’s instructions. Reference values for myostatin were 11–44 ng/ml.
Results. The prevalence of PEM, determined by the ISRNM method, was 24.9% (160 patients). The mean myostatin values in patients without signs of PEM were 31.2±16.2 ng/ml, and in patients with PEM – 76.7±25.5 ng/ml (P<0.0001). Patients with elevated myostatin levels had statistically significantly lower values of PEM indicators (body mass index, skeletal muscle mass index, as well as total protein, albumin, prealbumin, total cholesterol, transferrin and the number of blood lymphocytes) than patients with normal myostatin levels. At the same time, no statistically significant changes in body fat mass parameters depending on the myostatin level were detected. During the study, no significant relationship was found between the adequacy of the HD dose (spKt/V) and myostatin levels, which is confirmed, in particular, by the value of the Spearman correlation coefficient (Rs = 0.063; P = 0.106). In addition, there was no connection between the myostatin level and the duration of HD (Rs = 0.056; P = 0.151).
Conclusion. The prevalence of PEM, determined by the ISRNM method, in patients on program HD was 24.9%. An increase in the blood serum myostatin level may be an important pathogenetic link in the development of PEM in patients on program HD, mainly due to a negative effect on the patient’s muscle tissue.
Full Text
##article.viewOnOriginalSite##About the authors
Aleksandr A. Yakovenko
Pavlov University
Author for correspondence.
Email: leptin-rulit@mail.ru
ORCID iD: 0000-0003-1045-9336
Cand. Sci. (Med.), Associate Professor at the Department of Nephrology and Dialysis, Pavlov University
Russian Federation, St. PetersburgAshot M. Yesayan
Pavlov University
Email: essaian.ashot@gmail.com
ORCID iD: 0000-0002-7202-3151
Dr.Sci. (Med.), Professor, Head of the Department of Nephrology and Dialysis, Pavlov University, Chief External in Nephrology of the Northwestern Federal District of the Russian Federation
Russian Federation, St. PetersburgYulia V. Lavrishcheva
Almazov National Medical Research Center
Email: lavrischeva@gmail.com
ORCID iD: 0000-0002-3073-2785
Cand.Sci. (Med.), Associate Professor at the Department of Faculty Therapy with the Clinic, Almazov National Medical Research Center
Russian Federation, St. PetersburgAleksandr S. Rumyantsev
St. Petersburg State University
Email: rash.56@mail.ru
ORCID iD: 0000-0002-9455-1043
Dr.Sci. (Med.), Professor at the Department of Faculty Therapy, Faculty of Medicine, St. Petersburg State University
Russian Federation, St. PetersburgReferences
- Carrero J.J., Thomas F., Nagy K., et al. Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies From the International Society of Renal Nutrition and Metabolism. J. Ren. Nutr. 2018;28(6):380–92. doi: 10.1053/j.jrn.2018.08.006.
- Kang S.S., Chang J.W., Park Y. Nutritional Status Predicts 10-Year Mortality in Patients with End-Stage Renal Disease on Hemodialysis. Nutrients. 2017;9(4):pii:E399. doi: 10.3390/nu9040399.
- Obi Y., Qader H., Kovesdy C.P., Kalantar-Zadeh K. Latest consensus and update on protein-energy wasting in chronic kidney disease. Curr. Opin. Clin. Nutr. Metab. Care. 2015;18(3):254–62. doi: 10.1097/MCO.0000000000000171.
- Perez Vogt B., Costa Teixeira Caramori J. Are Nutritional Composed Scoring Systems and Protein-Energy Wasting Score Associated With Mortality in Maintenance Hemodialysis Patients? J. Ren. Nutr. 2016;26(3):183–89. doi: 10.1053/j.jrn.2015.11.003.
- Fouque D., Kalantar-Zadeh K., Kopple J., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391–98. doi: 10.1038/sj.ki.5002585.
- Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014;10(9):504–16. doi: 10.1038/nrneph.2014.112.
- Bataille S., Chauveau P., Fouque D., et al. Myostatin and muscle atrophy during chronic kidney disease. Nephrol. Dial. Transplant. 2021;36(11): 1986–93. doi: 10.1093/ndt/gfaa129.
- Pirruccello-Straub M., Jackson J., Wawersik S., et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 2018;8(1):2292. doi: 10.1038/s41598-018-20524-9.
- Verzola D., Barisione C., Picciotto D., et al. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney Int. 2019;95(3): 506–17. doi: 10.1016/j.kint.2018.10.010.
- Yano S., Nagai A., Isomura M., et al. Relationship between blood myostatin levels and kidney function: Shimane CoHRE study. PloS One. 2015;10(10):e0141035. Doi: 10/1371/jour.al.pone.0141035.
- Esposito P., Picciotto D., Battaglia Y., et al. Myostatin: Basic biology to clinical application. Adv. Clin. Chem. 2022;106:181–234. doi: 10.1016/bs.acc.2021.09.006.
Supplementary files
